Cite
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
MLA
Huynh, Hung, et al. “Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 14, no. 19, Oct. 2008, pp. 6146–53. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-08-0509.
APA
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., Pollock, P., Byron, S., & Tran, E. (2008). Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 14(19), 6146–6153. https://doi.org/10.1158/1078-0432.CCR-08-0509
Chicago
Huynh, Hung, Van Chanh Ngo, Joseph Fargnoli, Mark Ayers, Khee Chee Soo, Heng Nung Koong, Choon Hua Thng, et al. 2008. “Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 14 (19): 6146–53. doi:10.1158/1078-0432.CCR-08-0509.